TickerTalks
Browse all tickers →
TickerTalks›$RLAY
RLRLAY

Relay Therapeutics, Inc.

$RLAY·$2.8B·Biotechnology·Healthcare
$18.21+4.4%YTD+86.3%1Y+408.5%
Mentions · last 7 days
2026-06-14: 3 posts2026-06-15: 7 posts2026-06-16: 5 posts2026-06-17: 4 posts2026-06-18: 8 posts2026-06-19: 0 posts28
Price updated 10m ago·X counts updated 5d ago
RLRLAY
$RLAYRelay Therapeutics, Inc.
$18.21+4.39%28 posts
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $RLAY, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventAcceleratingAI verdict · as of 2026-06-24

The move is getting stronger, with heavier trading behind it.

Precision oncology up 408% in twelve months on zovegalisib Phase 2 data and a $275M raise.

Relay Therapeutics is up 408% trailing twelve months and 86% year-to-date at $17.44 (87% of 52-week range) on the strength of the May 19 initial Phase 2 ReInspire trial data for zovegalisib in vascular anomalies — a pivotal readout that re-rated the equity and supported the May 21 $275M follow-on offering at $12.00.

  • Q1 2026 EPS of -$0.41 missed -$0.35 by 17%, with revenue of $3.0M (-61% year-over-year); the trailing four-quarter EPS surprise track is mixed (-17%, +16%, -10%, +16%) and the revenue line is collaboration-deal-driven, not commercial.
  • The May 21 follow-on at $12.00 (22.9M shares + 3.44M overallotment) raised approximately $258.5M net — dilutive but funds the precision-oncology pipeline including the ReInspire Phase 2 trial and FGFR2/PI3Kα programs.
  • June 9 annual meeting: shareholders approved a Certificate of Amendment increasing authorized common shares from 300M to 450M — a 50% expansion that gives Relay significant additional capacity for future equity raises or M&A.
  • June 9 insider grants: seven directors each received 32,947 shares at $14.09 ($464K) — Claire Mazumdar, Mark Murcko, Lonnel Coats, Douglas Ingram, Alexis Borisy, Linda Hill and Habib Dable — no open-market sales.
  • FY26 consensus is -$1.57 EPS on $11.9M revenue; FY30 consensus steps to -$0.12 EPS on $466.6M revenue — the inflection is contingent on Phase 3 readouts.
  • Zovegalisib Phase 3 primary completion is April 2028; X chatter compares the setup to CELC and notes large July put sales going to $15 strike, with large June OI calls remaining.

Next earnings 2026-08-06.

Agrees with X sentimentX frames RLAY as a bull-case strong-day catalyst with CELC comp setup, July put sales at $15 strike, and large June calls; bear caveat is Zovega Phase 3 not until 2028. Our read agrees the operating-data narrative is intact; we flag the 450M-share authorization and the $275M dilution as the structural caveat the bull crowd isn't pricing.

What to watch: Q2 earnings Aug 6 — pipeline timeline updates; whether the $275M raise funds Phase 3 design changes; any RLY-2608 PI3Kα or RLY-4008 FGFR2 readouts.

On the calendar: 2026-08-06 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment9 posts analyzed · as of 2026-06-08

Relay Therapeutics is being framed as a bull-case strong-day catalyst: 'comparing to CELC' sets up RLAY favorably, surging pre-market with recent large July put sales going to $15 strike, and large June OI calls remaining. Bulls cite RLAY's mutant-selective program as the comp setup. The bear voice is contained — Zovega Ph3 primary completion not until April 2028.

Read the AI verdict + X sentiment for $RLAY

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops kinase inhibitor cancer drugs using protein motion simulation to design precision oncology therapies.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $RLAY.

Biotechnology · Healthcare

GLP-1 pipeline competition is the dominant structural driver — the ADA conference crystallized oral formulations, dual agonists, and differentiated mechanisms competing for a potential $150B obesity market by 2030. QURE's FDA accelerated approval for AMT-130 (Huntington's disease) this week confirms gene therapy regulatory momentum is still flowing capital to non-GLP-1 precision medicine.

What this means for $RLAY

Neutral — Relay Therapeutics' kinase inhibitor oncology drugs using protein motion simulation are precision oncology binary events; GLP-1 obesity pipeline competition doesn't intersect with kinase inhibitor mechanisms for solid tumors.

Top industry ETF

$IBBiShares Biotechnology ETF
+5.0%YTD
+42.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-8.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-44.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-27.8%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-9.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
221.6Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-43.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
89.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 5, 2026$-0.41$-0.35-17.1%
Q4 2025Feb 26, 2026$-0.32$-0.38+15.8%
Q3 2025Nov 6, 2025$-0.43$-0.39-10.3%
Q2 2025Aug 7, 2025$-0.41$-0.49+16.3%
Next earningsThu, Aug 6·consensus EPS $-0.41

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$3.0M-60.9%83.2%-2620%$-0.41$-51.1M
Q4 FY25$7.0M—91.4%-866%$-0.32$-44.9M
Q3 FY25$0———$-0.43$-62.1M
Q2 FY25$677K—100%-11351%$-0.41$-55.3M

Forward consensus

5-year forecast · up to 9 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$11.9M$4.3M – $22.8M-$1.57-$1.79 – -$1.329
FY27$19.6M$15.1M – $30.7M-$1.62-$1.76 – -$1.487
FY28$55.4M$42.7M – $86.6M-$1.52-$1.74 – -$1.229
FY29$186.6M$143.9M – $291.9M-$1.01-$1.75 – -$0.714
FY30$466.6M$359.9M – $729.7M-$0.12-$0.21 – -$0.094

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.87%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+10.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+68.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 136.0M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.755-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellMay 14Thomas CatinazzoCFO17.7K sh$228KSellApr 28Thomas CatinazzoCFO972 sh$14KSellApr 28Peter RahmerSee remarks753 sh$11KSellApr 28Donald A BergstromPresident1.5K sh$22KSellApr 9Thomas CatinazzoCFO1.8K sh$27KSellApr 7Thomas CatinazzoCFO17.7K sh$230KSellMar 9Thomas CatinazzoCFO17.7K sh$178KSellJan 28Donald A BergstromPresident2.7K sh$23KSellJan 28Thomas CatinazzoCFO1.7K sh$14KSellJan 28Peter RahmerSee remarks1.4K sh$11K
1–10 of 14
+ 14 other (13 awards · 1 exempt) in window

See when $RLAY insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KCharter amendmentJun 98-K — Item 5.03: Charter amendment · Item 5.07: Shareholder vote
AI summary

Relay Therapeutics (RLAY) held its 2026 Annual Meeting on June 9, 2026, electing Class III directors Douglas Ingram (120.9M for) and Claire Mazumdar (122.9M for) to three-year terms through 2029. Separately, stockholders approved — and Relay immediately filed — a Certificate of Amendment increasing authorized common shares from 300 million to 450 million. The 50% authorized share expansion (approved by a majority of votes cast) was the most material action at the meeting, giving Relay significant additional capacity for future equity raises or acquisitions.

8-KMaterial agreementMay 218-K — Item 1.01: Material agreement
AI summary

Relay Therapeutics, Inc. (RLAY) filed an 8-K on May 20, 2026 disclosing a material definitive agreement (Item 1.01). Relay is a Cambridge, Massachusetts-based clinical-stage precision medicine company focused on protein motion science, listed on Nasdaq. Filed concurrently with Relay's $275M equity offering (424B5), this material agreement may relate to a licensing, collaboration, or acquisition that the equity raise is intended to support; the specific terms and counterparty are not visible in the excerpt.

424B5Prospectus supplement (offering)May 21424B5
AI summary

Relay Therapeutics, Inc. (RLAY) priced a public offering of 22,916,667 shares of common stock at $12.00 per share for gross proceeds of approximately $275 million, per a 424B5 filed May 21, 2026; the underwriting discount is $0.72/share ($16.5M total), yielding net proceeds of ~$258.5M before expenses, with a 30-day overallotment option for 3,437,500 additional shares. The offering price represents a modest discount to the last sale price of $12.20. This is a large dilutive primary equity raise for Relay Therapeutics, likely funding its precision oncology and protein motion drug discovery programs.

424B5Prospectus supplement (offering)May 19424B5
AI summary

Relay Therapeutics, Inc. (RLAY) filed a preliminary prospectus supplement for an underwritten public offering of $175 million of common stock, with a 30-day overallotment option for an additional $26.25 million, led by Jefferies, TD Cowen, Goldman Sachs, and Guggenheim Securities. The last reported sale price on May 15, 2026 was $12.20 per share; final per-share price and share count are not set in this preliminary supplement. This is a dilutive equity raise for a clinical-stage biotech, likely to fund the ReInspire Phase 2 trial of zovegalisib and other pipeline development.

8-KPress release / Reg FDMay 198-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Relay Therapeutics, Inc. (RLAY) released initial Phase 2 ReInspire trial clinical data for zovegalisib in vascular anomalies via Reg FD press release (Exhibit 99.1) and a slide presentation (Exhibit 99.2) on May 19, 2026, with a live conference call and webcast at 8:00 a.m. ET. This represents a pivotal Phase 2 data readout for zovegalisib in a rare vascular indication, with efficacy and safety results that could define the drug's further development path and materially impact the company's pipeline value.

8-KPress release / Reg FDApr 278-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

RLAY filed an 8-K Item 7.01 (Reg FD) disclosure dated 2026-04-27. Covers: slide presentation to accompany the call, a copy of which is being furnished as Exhibit 99. Reg FD disclosures make material information simultaneously available to all investors; content may include guidance updates, strategic plans, or preliminary results.

8-KPress release / Reg FDMar 168-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
8-KCharter amendmentMar 118-K — Item 5.03: Charter amendment
+ 16 other (6 13Gs · 2 earnings 8-Ks · 2 proxys · 1 10-Q) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Relay Therapeutics, Inc. (RLAY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.com·16d agoRelay Therapeutics to Participate in Two Upcoming Investor Conferences in Juneglobenewswire.com·28d agoIs Relay Therapeutics a Buy After Promising Trial Results?fool.com·33d agoRelay Therapeutics Announces Pricing of Public Offering of Common Stockglobenewswire.com·35d agoRelay Therapeutics Announces Pricing of Public Offering of Common Stockglobenewswire.com·35d ago

In themes

Explore the broader themes this ticker is being talked about under.

AI Precision Medicine

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$AURA$QURE$DFTX$ALLO$HUMA$ALT$IBRX$APGE
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport